CYCLOPHOSPHAMIDE-INDUCED CYSTITIS IN FREELY-MOVING CONSCIOUS RATS: BEHAVIORAL APPROACH TO A NEW MODEL OF VISCERAL PAIN

No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Jul 2000CYCLOPHOSPHAMIDE-INDUCED CYSTITIS IN FREELY-MOVING CONSCIOUS RATS: BEHAVIORAL APPROACH TO A NEW MODEL OF VISCERAL PAIN MICHEL BOUCHER, MURIELLE MEEN, JEAN-PAUL CODRON, FRANCOIS COUDORE, JEAN-LOUIS KEMENY, and ALAIN ESCHALIER MICHEL BOUCHERMICHEL BOUCHER More articles by this author , MURIELLE MEENMURIELLE MEEN More articles by this author , JEAN-PAUL CODRONJEAN-PAUL CODRON More articles by this author , FRANCOIS COUDOREFRANCOIS COUDORE More articles by this author , JEAN-LOUIS KEMENYJEAN-LOUIS KEMENY More articles by this author , and ALAIN ESCHALIERALAIN ESCHALIER More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67495-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: To develop a model of visceral pain in rats using a behavioral approach. Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis. Materials and Methods: CP was administered at doses of 50, 100 and 200 mg./kg. i.p. to male rats, and their behavior observed and scored. The effects of morphine (0.5 to 4 mg./kg. i.v.) on CP-induced behavioral modifications were tested administered alone and after naloxone (1 mg./kg. s.c.). In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination. Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg. i.p. and of 20 mg. by the intravesical route, and acrolein at doses of 0.5 mg. by the intravesical route and of 5 mg./kg. i.v. Results: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures. Morphine dose-dependently reversed these behavioral disorders. A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg. This effect was completely prevented by pretreatment with naloxone. At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed. In female rats, CP 200 mg./kg. i.p. produced the same marked behavioral modifications as those observed in male rats. Administered at the dose of 20 mg. intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg. intravesically induced behavioral modifications identical to those under CP 200 mg./kg. i.p., with the same maximal levels. Conversely, acrolein 5 mg./kg. i.v. did not produce any behavioral effects at all. Conclusions: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them. References 1 : A model for the study of visceral pain states: chronic inflammation of the chronic decerebrate rat urinary bladder by irritant chemicals. Pain1987; 28: 109. Google Scholar 2 : A method for studying pain arising from the urinary bladder in conscious, freely-moving rats. J Urol1989; 141: 148. Link, Google Scholar 3 : Influence of the nervous system on experimentally induced urethral inflammation. Neurosci Lett1990; 115: 183. Google Scholar 4 : Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat. J Neurosci1992; 12: 4878. Google Scholar 5 : Behavioral responses to uterine or vaginal distension in the rat. Pain1995; 61: 121. Google Scholar 6 : Artificial ureteral calculosis in rats: behavioural characterization of visceral pain episodes and their relationship with referred lumbar muscle hyperalgesia. Pain1995; 61: 459. Google Scholar 7 : Acetylcysteine in the prevention of cyclophosphamide-induced cystitis in rats. J Natl Cancer Inst1973; 51: 1051. Google Scholar 8 : Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur J Cancer Clin Oncol1981; 17: 1155. Google Scholar 9 : Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (cytoxan) therapy. J Urol1986; 136: 497. Link, Google Scholar 10 : The use of prostaglandin F2 alpha for the prophylaxis of cyclophosphamide-induced cystitis in rats. J Urol1990; 144: 1500. Abstract, Google Scholar 11 : Hyperbaric oxygen treatment for experimental cyclophosphamide-induced hemorrhagic cystitis. J Urol1993; 149: 1617. Link, Google Scholar 12 : Treatment of cyclophosphamide-induced hemorrhagic cystitis with intravesical carboprost tromethamine. J Urol1993; 149: 719. Link, Google Scholar 13 : Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol1993; 11: 1306. Google Scholar 14 : Prevention of hemorrhagic cystitis following allogeneic bone marrow transplant preparative regimens with cyclophosphamide and busulfan: role of continuous bladder irrigation. J Urol1995; 153: 637. Link, Google Scholar 15 : Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem Pharmacol1979; 28: 2045. Google Scholar 16 : The development of MESNA for regional detoxification. Cancer Treat Rev1983; 10: 33. Google Scholar 17 : Cyclophosphamide cystitis as a model of visceral pain in rats: model elaboration and spinal structures involved as revealed by the expression of c-Fos and Krox-24 proteins. Exp Brain Res1995; 105: 220. Google Scholar 18 : Cyclophosphamide cystitis as a model of visceral pain in rats. A survey of hindbrain structures involved in visceroception and nociception using the expression of c-Fos and Krox-24 proteins. Exp Brain Res1996; 108: 404. Google Scholar 19 : Experimental cytoxan cystitis and prevention by acetylcysteine. J Urol1985; 134: 598. Link, Google Scholar 20 : Cyclophosphamide cystitis in mice: behavioural characterisation and correlation with bladder inflammation. Eur J Pain1999; 3: 141. Google Scholar 21 : The veterinarian’s responsibility: assessing and managing acute pain in dogs and cats. Part I. Compend Contin Educ Practic Vet1991; 13: 804. Google Scholar 22 : The veterinarian’s responsibility: assessing and managing acute pain in dogs and cats. Part II. Compend Contin Educ Practic Vet1991; 13: 911. Google Scholar 23 : Opioid analgesics and antagonists. In: . New York: International Edition-McGraw Hill1996: 521. chapt 23. Google Scholar 24 : A comparison of the lethal and respiratory effects of morphine in Long-Evans and Sprague-Dawley rats. Arch Int Pharmacodyn1969; 182: 130. Google Scholar 25 : Respiratory effects of morphine in awake unrestrained rats. J Pharmacol Exp Ther1986; 237: 252. Google Scholar 26 : Dissociated effects of inhibitors of enkephalin-metabolizing peptidases or naloxone on various nociceptive responses. Eur J Pharmacol1986; 123: 37. Google Scholar 27 : Opioids. In: . New York: Churchill Livingstone1994: 943. chapt 49. Google Scholar 28 : Opioid agonists and antagonists: an evaluation of their peripheral actions in inflammation. Med Res Rev1992; 12: 525. Google Scholar 29 : Peripheral mechanisms of opioid analgesia. Anesth Analg1993; 76: 182. Google Scholar 30 : Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 1. Experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer1981; 17: 595. Google Scholar From Inserm EPI9904 (Laboratoire de Physiologie, Laboratoire de Pharmacologie, and Laboratoire de Toxicologie, Faculté de Pharmacie), the Laboratoire d’Anatomie-Pathologique, CHU Gabriel Montpied, and the Laboratoire de Pharmacologie Médicale, Faculté de Médecine, University of Auvergne, Clermont-Ferrand, France© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byPessina F, Capasso R, Borrelli F, Aveta T, Buono L, Valacchi G, Fiorenzani P, Di Marzo V, Orlando P and Izzo A (2018) Protective Effect of Palmitoylethanolamide in a Rat Model of CystitisJournal of Urology, VOL. 193, NO. 4, (1401-1408), Online publication date: 1-Apr-2015.Takahara Y, Suzuki A, Maeda M, Kawashima H, Nakatani T and Kiyama H (2018) Expression of Pancreatitis Associated Proteins in Urothelium and Urinary Afferent Neurons Following Cyclophosphamide Induced CystitisJournal of Urology, VOL. 179, NO. 4, (1603-1609), Online publication date: 1-Apr-2008.BON K, LICHTENSTEIGER C, WILSON S and MOGIL J (2018) Characterization of Cyclophosphamide Cystitis, a Model of Visceral and Referred Pain, in the Mouse: Species and Strain DifferencesJournal of Urology, VOL. 170, NO. 3, (1008-1012), Online publication date: 1-Sep-2003.MEEN M, COUDORE-CIVIALE M, ESCHALIER A and BOUCHER M (2018) INVOLVEMENT OF HYPOGASTRIC AND PELVIC NERVES FOR CONVEYING CYSTITIS INDUCED NOCICEPTION IN CONSCIOUS RATSJournal of Urology, VOL. 166, NO. 1, (318-322), Online publication date: 1-Jul-2001. Volume 164Issue 1July 2000Page: 203-208 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsurinary bladderbehavioral approachvisceral paincystitiscyclophosphamideratMetricsAuthor Information MICHEL BOUCHER More articles by this author MURIELLE MEEN More articles by this author JEAN-PAUL CODRON More articles by this author FRANCOIS COUDORE More articles by this author JEAN-LOUIS KEMENY More articles by this author ALAIN ESCHALIER More articles by this author Expand All Advertisement PDF downloadLoading ...